Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 6/20 | 0.37 |
| ▸ | FBP1 | P09467 | 6/20 | 0.37 |
| ▸ | CA12 | O43570 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23699726 | 0.86 | CYP2D6 (0.52) | CYP2D6TSHRTPSAB1TPSD1TPSG1 | |
| SCHEMBL23699758 | 0.82 | CYP2D6 (0.50) | CYP2D6TSHRELANECA9FBP1 | |
| SCHEMBL21855131 | 0.77 | CYP2D6 (0.46) | CYP2D6TSHRELANECA9FBP1 | |
| SCHEMBL23732688 | 0.70 | CYP2D6 (0.56) | CYP2D6TSHRELANECA9FBP1 | |
| SCHEMBL11443197 | 0.66 | CYP2D6 (0.59) | CYP2D6TSHRELANECA9FBP1 | |
| SCHEMBL23699755 | 0.65 | CYP2D6 (0.68) | CYP2D6TSHRELANECA9FBP1 | |
| SCHEMBL23732623 | 0.65 | CYP2D6 (0.54) | CYP2D6TSHRTPSAB1TPSD1TPSG1 | |
| SCHEMBL5121655 | 0.64 | BCHE (0.54) | CA9CA12 | |
| SCHEMBL9479383 | 0.64 | ALDH1A1 (0.38) | POLBGAAHPGD | |
| SCHEMBL15033556 | 0.63 | LMNA (0.40) | CA9CA12PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391886-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| EP-3866773-B1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | UNIV GEORGIA STATE RES FOUND (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12071415-B2 | Carbon monoxide prodrugs for the treatment of medical disorders | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20210238155-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238155-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | PYGL, HMOX2, MB | CYP2D6 47/4885TSHR 4002/4885TPSAB1 778/4885 |
| US-20240391886-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | PYGL, HMOX2, MB | CYP2D6 47/4885TSHR 4002/4885TPSAB1 778/4885 |
| US-12071415-B2 | Carbon monoxide prodrugs for the treatment of medical disorders | PYGL, HMOX2, MB | CYP2D6 47/4885TSHR 4002/4885TPSAB1 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.